217 related articles for article (PubMed ID: 29440175)
1. Pan-Cancer Molecular Classes Transcending Tumor Lineage Across 32 Cancer Types, Multiple Data Platforms, and over 10,000 Cases.
Chen F; Zhang Y; Gibbons DL; Deneen B; Kwiatkowski DJ; Ittmann M; Creighton CJ
Clin Cancer Res; 2018 May; 24(9):2182-2193. PubMed ID: 29440175
[No Abstract] [Full Text] [Related]
2. Pan-urologic cancer genomic subtypes that transcend tissue of origin.
Chen F; Zhang Y; Bossé D; Lalani AA; Hakimi AA; Hsieh JJ; Choueiri TK; Gibbons DL; Ittmann M; Creighton CJ
Nat Commun; 2017 Aug; 8(1):199. PubMed ID: 28775315
[TBL] [Abstract][Full Text] [Related]
3. Conservation of immune gene signatures in solid tumors and prognostic implications.
Chifman J; Pullikuth A; Chou JW; Bedognetti D; Miller LD
BMC Cancer; 2016 Nov; 16(1):911. PubMed ID: 27871313
[TBL] [Abstract][Full Text] [Related]
4. Pan-cancer survey of epithelial-mesenchymal transition markers across the Cancer Genome Atlas.
Gibbons DL; Creighton CJ
Dev Dyn; 2018 Mar; 247(3):555-564. PubMed ID: 28073171
[TBL] [Abstract][Full Text] [Related]
5. A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition.
Mak MP; Tong P; Diao L; Cardnell RJ; Gibbons DL; William WN; Skoulidis F; Parra ER; Rodriguez-Canales J; Wistuba II; Heymach JV; Weinstein JN; Coombes KR; Wang J; Byers LA
Clin Cancer Res; 2016 Feb; 22(3):609-20. PubMed ID: 26420858
[TBL] [Abstract][Full Text] [Related]
6. Investigation of lipid metabolism dysregulation and the effects on immune microenvironments in pan-cancer using multiple omics data.
Hao Y; Li D; Xu Y; Ouyang J; Wang Y; Zhang Y; Li B; Xie L; Qin G
BMC Bioinformatics; 2019 May; 20(Suppl 7):195. PubMed ID: 31074374
[TBL] [Abstract][Full Text] [Related]
7. Genomic Characterization of Six Virus-Associated Cancers Identifies Changes in the Tumor Immune Microenvironment and Altered Genetic Programs.
Varn FS; Schaafsma E; Wang Y; Cheng C
Cancer Res; 2018 Nov; 78(22):6413-6423. PubMed ID: 30254145
[TBL] [Abstract][Full Text] [Related]
8. Expression patterns of small numbers of transcripts from functionally-related pathways predict survival in multiple cancers.
Mandel J; Wang H; Normolle DP; Chen W; Yan Q; Lucas PC; Benos PV; Prochownik EV
BMC Cancer; 2019 Jul; 19(1):686. PubMed ID: 31299925
[TBL] [Abstract][Full Text] [Related]
9. An integrative and comparative study of pan-cancer transcriptomes reveals distinct cancer common and specific signatures.
Cao Z; Zhang S
Sci Rep; 2016 Sep; 6():33398. PubMed ID: 27633916
[TBL] [Abstract][Full Text] [Related]
10. Sequential analysis of transcript expression patterns improves survival prediction in multiple cancers.
Mandel J; Avula R; Prochownik EV
BMC Cancer; 2020 Apr; 20(1):297. PubMed ID: 32264880
[TBL] [Abstract][Full Text] [Related]
11. Application of a Neural Network Whole Transcriptome-Based Pan-Cancer Method for Diagnosis of Primary and Metastatic Cancers.
Grewal JK; Tessier-Cloutier B; Jones M; Gakkhar S; Ma Y; Moore R; Mungall AJ; Zhao Y; Taylor MD; Gelmon K; Lim H; Renouf D; Laskin J; Marra M; Yip S; Jones SJM
JAMA Netw Open; 2019 Apr; 2(4):e192597. PubMed ID: 31026023
[TBL] [Abstract][Full Text] [Related]
12. Genomic pathway analysis reveals that EZH2 and HDAC4 represent mutually exclusive epigenetic pathways across human cancers.
Cohen AL; Piccolo SR; Cheng L; Soldi R; Han B; Johnson WE; Bild AH
BMC Med Genomics; 2013 Sep; 6():35. PubMed ID: 24079712
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive analyses of tumor immunity: implications for cancer immunotherapy.
Li B; Severson E; Pignon JC; Zhao H; Li T; Novak J; Jiang P; Shen H; Aster JC; Rodig S; Signoretti S; Liu JS; Liu XS
Genome Biol; 2016 Aug; 17(1):174. PubMed ID: 27549193
[TBL] [Abstract][Full Text] [Related]
14. Machine Learning Identifies Pan-Cancer Landscape of Nrf2 Oxidative Stress Response Pathway-Related Genes.
Li N; Zhan X
Oxid Med Cell Longev; 2022; 2022():8450087. PubMed ID: 35242279
[TBL] [Abstract][Full Text] [Related]
15. Impact of Tumor Purity on Immune Gene Expression and Clustering Analyses across Multiple Cancer Types.
Rhee JK; Jung YC; Kim KR; Yoo J; Kim J; Lee YJ; Ko YH; Lee HH; Cho BC; Kim TM
Cancer Immunol Res; 2018 Jan; 6(1):87-97. PubMed ID: 29141981
[TBL] [Abstract][Full Text] [Related]
16. Distinct signatures of codon and codon pair usage in 32 primary tumor types in the novel database CancerCoCoPUTs for cancer-specific codon usage.
Meyer D; Kames J; Bar H; Komar AA; Alexaki A; Ibla J; Hunt RC; Santana-Quintero LV; Golikov A; DiCuccio M; Kimchi-Sarfaty C
Genome Med; 2021 Jul; 13(1):122. PubMed ID: 34321100
[TBL] [Abstract][Full Text] [Related]
17. Hypermethylation in histologically distinct classes of breast cancer.
Bae YK; Brown A; Garrett E; Bornman D; Fackler MJ; Sukumar S; Herman JG; Gabrielson E
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):5998-6005. PubMed ID: 15447983
[TBL] [Abstract][Full Text] [Related]
18. The panoramic picture of pepsinogen gene family with pan-cancer.
Shen S; Li H; Liu J; Sun L; Yuan Y
Cancer Med; 2020 Dec; 9(23):9064-9080. PubMed ID: 33067881
[TBL] [Abstract][Full Text] [Related]
19. Pan-cancer genomic analysis links 3'UTR DNA methylation with increased gene expression in T cells.
McGuire MH; Herbrich SM; Dasari SK; Wu SY; Wang Y; Rupaimoole R; Lopez-Berestein G; Baggerly KA; Sood AK
EBioMedicine; 2019 May; 43():127-137. PubMed ID: 31056473
[TBL] [Abstract][Full Text] [Related]
20. Systematic Pan-Cancer Analysis Identifies TREM2 as an Immunological and Prognostic Biomarker.
Cheng X; Wang X; Nie K; Cheng L; Zhang Z; Hu Y; Peng W
Front Immunol; 2021; 12():646523. PubMed ID: 33679809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
